We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

DCO:NYSEDucommun Incorporated Analysis

Data as of 2026-08-10 - not real-time

$197.07

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

At $197.07, Ducommun Incorporated shows a bullish moving-average alignment, with shorter averages sitting above longer ones. It has gained 15.6% over the past 30 days. Momentum indicators put RSI at 64.0 (approaching overbought) with MACD reading bullish. The recent range runs from support at $161.87 up to resistance at $210.39.
On valuation the read is overvalued — earnings multiple of 37.0 versus a 30.7 sector average, above the peer group. Revenue is growing at 11.8% on a -2.5% profit margin.
The composite risk read is 7/10, putting it in elevated territory. With 30-day volatility of 51.9%, a beta of 1.41 and a maximum drawdown of 16.0%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 94 on the fear-greed composite.
Timeframes disagree: the short-term read is buy while the long-term read is hold, conviction 2 out of 10.

Top Market Events

COSTA MESA, Calif., July 23, 2026 GLOBE NEWSWIRE -- Ducommun Incorporated NYSE: DCO “Ducommun” or the “Company”...COSTA MESA, Calif., Aug. 06, 2026 GLOBE NEWSWIRE -- Ducommun Incorporated NYSE: DCO “Ducommun” or the “Company”...Ducommun Incorporated NYSE:DCO is among the 8 Best Mid Cap Defense Stocks to Buy, with 18 hedge funds having a stake in...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 4/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 129.80
  • MACD momentum is positive

Medium Term

1–3 years
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 37.0 versus sector average of 30.7
  • Trading above the 200-day average of 129.80

Long Term

> 3 years
Neutral
Model confidence: 2/10

Key Factors

  • P/E of 37.0 versus sector average of 30.7
  • Negative profit margin of -2.5%
  • Negative return on equity of -3.0%

Key Metrics & Analysis

Financial Health

Revenue Growth11.80%
Profit Margin-2.45%
P/E Ratio37.0
ROE-3.03%
ROA4.97%
Debt/Equity48.49
P/B Ratio4.3
Op. Cash Flow$-11800000
Free Cash Flow$57.5M
Industry P/E30.7

Technical Analysis

TrendBullish
RSI64.0
Support$161.87
Resistance$210.39
MA 20$178.67
MA 50$170.67
MA 200$129.80
MACDBullish
VolumeDecreasing
Fear & Greed Index93.84

Valuation

Fair Value$60.58
Target Price$197.80
Upside/Downside0.37%
GradeOvervalued
TypeGrowth

Risk Assessment

Beta1.41
Volatility51.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.